Journal article
A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas
Cancers, Vol.12(7), pp.1-10
07/01/2020
DOI: 10.3390/cancers12071873
PMCID: PMC7408640
PMID: 32664595
Abstract
Although checkpoint inhibitors have been approved in multiple cancers, they are still under investigation in soft tissue sarcoma (STS). We conducted a retrospective review to report the safety, efficacy, and prognostic factors related to checkpoint inhibitors in STS. A sequential cohort of metastatic STS patients from four institutions treated with checkpoint inhibitors was assembled. Logistic and Cox regression models were applied to determine the effect of patient characteristics, prior treatment, and baseline factors on achieving the best overall response of complete response (CR), partial response (PR), or stable disease (SD) as determined by the treating physician. Eighty-eight patients with two median prior therapies received checkpoint inhibitors. Treatments included pembrolizumab in 47, nivolumab in 6, ipilimumab in 1, combination ipilimumab/nivolumab in 27, and other combination immunotherapies in 7 patients. Immunotherapy was discontinued in 54 patients-72.2% for progression, 16.7% for toxicity, and 11.1% for other reasons. Median progression-free survival (PFS) was 4.1 months and median overall survival was 19.1 months. One patient with undifferentiated pleomorphic sarcoma (UPS) achieved a CR, while 20 patients had a PR, including 7 UPS, 9 leiomyosarcoma (LMS), and 1 each with alveolar soft part sarcoma, fibroblastic sarcoma, sclerosing epithelioid fibrosarcoma, and myxofibrosarcoma. Forty-five percent (9 of 20) of LMS patients achieved a PR. Twenty-eight patients had SD. Our results confirm the activity and safety of anti-PD-1 therapy in metastatic STS. A notable response rate was observed in UPS and LMS subtypes. This study expands the knowledge base beyond what is currently available from clinical trials involving checkpoint inhibitors in metastatic STS.
Details
- Title: Subtitle
- A Retrospective Analysis of the Efficacy of Immunotherapy in Metastatic Soft-Tissue Sarcomas
- Creators
- Varun Monga - University of IowaKeith M. Skubitz - University of MinnesotaSeth Maliske - University of IowaSarah L. Mott - University of IowaHilary Dietz - Washington University in St. LouisAngela C. Hirbe - Washington University in St. LouisBrian A. Van Tine - Washington University in St. LouisPeter Oppelt - Washington University in St. LouisScott Okuno - Mayo ClinicSteven Robinson - Mayo ClinicMadeline O'Connor - Mayo ClinicMahesh Seetharam - Mayo Clinic in ArizonaSteven Attia - Mayo Clinic in FloridaJohn Charlson - Medical College of WisconsinMark Agulnik - Northwestern UniversityMohammed Milhem - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Cancers, Vol.12(7), pp.1-10
- DOI
- 10.3390/cancers12071873
- PMID
- 32664595
- PMCID
- PMC7408640
- NLM abbreviation
- Cancers (Basel)
- ISSN
- 2072-6694
- eISSN
- 2072-6694
- Publisher
- Mdpi
- Number of pages
- 10
- Grant note
- K12 CA90628 / Foundation for National Institute of Health 3P30CA086862-14S1 / National Cancer Institute; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) 75207 / Robert Wood Johnson Foundation Center for Health Policy; Robert Wood Johnson Foundation (RWJF) UL1TR002537 / National Center of Advancing Translational Sciences
- Language
- English
- Date published
- 07/01/2020
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359689302771
Metrics
20 Record Views